pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,071 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1801Endpoints1403Fierce Biotech720BioSpace712BioPharma Dive530raps239onclive165fda recalls114
therapy area
allOncology12439Rare Disease3241Immunology2910Cardiology2788Hematology2198Pulmonology2154Vaccines1818
  • Zentalis reports promising overall survival and response rates for oral WEE1 inhibitor azenosertib in platinum-resistant ovarian cancer
    Zentalis Pharmaceuticals presented early data from the phase 1b portion of its Denali study of azenosertib, an oral WEE1 tyrosine kinase inhibitor, in patients with platinum‑resistant ovarian cance…
    Fierce Biotech · 21d agoPositive readoutPositive↗ source
  • Researchers identify cellular stress trigger behind Angelman syndrome
    Researchers at Washington University School of Medicine in St. Louis reported a new mechanism linking loss of the maternal UBE3A gene to neuronal stress in Angelman syndrome. The study, published…
    Fierce Biotech · 21d agoPositive↗ source
← prev
page 9 of 43
next →
fda medwatch112
globenewswire health73
fda press59
Psychiatry & CNS1212
Ophthalmology1074
Endocrinology & Metabolism782
Pain780
Nephrology764
  • Quest Diagnostics reports cyberattack that may have exposed patient records
    Quest Diagnostics disclosed in an SEC filing that its Quanum LSM system was accessed without authorization on Oct 21, potentially compromising patient data. The breach affected a system used by ce…
    Fierce Biotech · 21d agoRegulatoryNegative↗ source
  • Rebranded Rezera plans IPO to fund phase 3 trial of NLRP3 inhibitor ruvonoflast for peripheral artery disease
    Rezera, which rebranded from NodThera last month, announced plans for an initial public offering to raise capital for its lead candidate, ruvonoflast, a brain‑penetrant NLRP3 inhibitor. The compan…
    Fierce Biotech · 22d agoDealPositive↗ source
  • Roche CEO says stance on $1.5B Poseida acquisition unchanged despite dropping one CAR-T program
    Roche bought Poseida in 2024 for $1.5 billion to secure its off-the-shelf CAR-T platform and strengthen its cell-therapy portfolio. During the third-quarter earnings call, the company said it has…
    Fierce Biotech · 22d agoDealNeutral↗ source
  • GSK’s B7-H4 ADC shows 62% response in platinum-resistant ovarian cancer, PFS 11 months
    GSK’s global head of oncology R&D presented new early-stage data on its B7-H4‑directed antibody‑drug conjugate, mo‑rez, at the ESMO conference in Madrid. The update focused on the ongoing Behold‑1…
    Fierce Biotech · 22d agoPositive readoutPositive↗ source
  • FDA issues warning letters to Baxter and Olympus over GMP and QSR violations
    The U.S. Food and Drug Administration sent formal warning letters to Baxter International and Olympus Medical Systems. The letters allege that both companies failed to meet required good manufactu…
    raps · 22d agoRegulatoryNegative↗ source
  • AbbVie’s lutikizumab meets primary endpoint in phase 3 hidradenitis suppurativa trial but falls short of competitive benchmarks
    AbbVie reported that its experimental antibody lutikizumab achieved the primary endpoint in the phase 3 Intrepid study for hidradenitis suppurativa. The trial enrolled about 1,400 patients and at…
    Fierce Biotech · 21d agoPositive readoutNeutral↗ source
  • Boehringer presents phase 1b data on obrixtamig showing strong response rates in second-line small cell lung cancer
    Boehringer Ingelheim presented updated data from its DAREON-9 phase 1b trial at the ESMO Congress in Madrid, evaluating the DLL3xCD3 bispecific T-cell engager obrixtamig in combination with topotec…
    Fierce Biotech · 21d agoPositive readoutPositive↗ source
  • Abbott to separate Nutrition business into independent publicly traded company
    Abbott announced it will separate its Nutrition business into a stand-alone publicly traded company. The spin‑off will be carried out via a tax‑free distribution of the new company's shares to Abb…
    Fierce Biotech · 22d agoNeutral↗ source
  • Ipsen executive urges scientists to look beyond first results to achieve patient impact
    Philippe Lopes-Fernandes, executive vice president and chief business officer at Ipsen, reflects on how scientific progress often requires moving past an initial finding. He notes that a result can…
    Fierce Biotech · 21d agoPositive↗ source
  • EMA opens consultation on platform trial methodology; MHRA to recognize CE-marked devices indefinitely
    The European Medicines Agency is launching a public consultation to gather feedback on the methodological aspects of confirmatory platform clinical trials. The agency seeks input from researchers,…
    raps · 22d agoRegulatoryNeutral↗ source
  • Roche reports up to 30% shrinkage of chronic MS lesions with fenebrutinib, eyes FDA approval
    Roche has filed for FDA approval of its BTK inhibitor fenebrutinib for both relapsing and primary progressive multiple sclerosis, after the agency accepted the submission. At the MSToronto2026 mee…
    Fierce Biotech · 22d agoPositive readoutPositive↗ source
  • Merck and Moderna release early phase 3 melanoma vaccine data showing primary endpoint success but weaker secondary results
    Merck and Moderna disclosed phase 3 data for their melanoma vaccine INTerpath-001 ahead of schedule after an embargo breach. The trial met its primary endpoint of recurrence‑free survival, with re…
    Fierce Biotech · 23d agoPositive readoutNeutral↗ source
  • Hologic acquires Spain’s Reveal Genomics to expand breast cancer genomic testing
    Hologic, a medical‑technology company, announced it will acquire precision‑oncology firm Reveal Genomics, based in Spain. Reveal Genomics develops advanced genomic diagnostic tests, notably the HE…
    Fierce Biotech · 23d agoDealPositive↗ source
  • Astellas partners with AI Proteins on $400M computational drug discovery deal
    Astellas Pharma of Japan has entered a partnership with Boston based AI Proteins to apply its computational design platform to drug discovery. AI Proteins builds miniproteins from scratch using ar…
    Fierce Biotech · 22d agoDealPositive↗ source
  • Biotech reverse mergers surge in 2026, reaching highest level since 2021 as PIPE financing spikes
    Biotech companies are using reverse mergers to re‑enter public markets at a rate not seen since 2021, according to a J.P. Morgan report released in October 2026. In the first nine months of 2026,…
    Fierce Biotech · 23d agoDealPositive↗ source
  • Myriad Genetics sells prenatal testing business to Labcorp for $210 million
    Myriad Genetics announced it will divest its Prenatal Health testing division to Labcorp, receiving $210 million in cash. The transaction includes Myriad's Prequel, Foresight, SneakPeek and FirstG…
    Fierce Biotech · 23d agoDealNeutral↗ source
  • FDA device officials prioritize hiring after layoffs, express optimism for upcoming MDUFA VI agreement
    Top officials from the FDA's Center for Devices and Radiological Health spoke at a town‑hall session during The MedTech Conference. They said the agency is concentrating on rebuilding staff after a…
    raps · 23d agoRegulatoryPositive↗ source
  • Amid bepirovirsen triumph, GSK quietly scraps trial of next-gen hep B therapy
    GSK may have cemented its hepatitis B credentials with Tuesday’s landmark FDA nod for its “functional cure” bepirovirsen, but the pharma continues to rethink its strategy for next-gen candidates.
    Fierce Biotech · 22d agoRegulatoryNeutral↗ source
  • Pharma companies push FDA for risk-based flexibility in container-closure testing guidance
    Major pharma firms have written to the FDA urging a shift in its current guidance on testing container-closure systems for drug and biologic products. They argue that a risk-based, flexible approa…
    raps · 23d agoRegulatoryNeutral↗ source
  • Researchers develop tumor "avatar" model that predicts immunotherapy response with 93% accuracy
    Researchers at Elephas Biosciences, in collaboration with academic centers, created an ex vivo tumor "avatar" from patient biopsies to test how tumors respond to immunotherapy. They exposed 124 tu…
    Fierce Biotech · 23d agoPositive readoutPositive↗ source
  • AstraZeneca teams with Oracle on AI-driven clinical trials as FDA clears Haemonetics vascular closure system
    AstraZeneca announced a collaboration with technology firm Oracle to incorporate artificial intelligence into its clinical trial processes. The partnership aims to use Oracle's cloud and data analy…
    raps · 24d agoApprovalPositive↗ source
  • Rapport Therapeutics' Phase 2 Bipolar Mania Trial Meets Primary Endpoint, Though Effect Size Below Target
    Rapport Therapeutics reported that its phase 2 study of RAP-219 in bipolar mania met the primary endpoint, showing a statistically significant improvement on the Young Mania Rating Scale (YMRS) at…
    Fierce Biotech · 23d agoPositive readoutNeutral↗ source
  • Bristol Myers Squibb leads $237 million Series E for Pathos AI and launches Alzheimer's collaboration
    Bristol Myers Squibb (BMS) headed a financing round that raised $237 million for biotech Pathos AI. The Series E funding will support Pathos AI's development of its AI‑driven platform for drug dis…
    Fierce Biotech · 24d agoDealPositive↗ source